Emerging therapeutic strategies to enhance HDL function
1 Department of Pharmacology, School of Medicine, Universidad Complutense de Madrid, Spain
2 Service of Hematology, Hospital Nuestra Señora de Sonsoles, Ávila, Spain
3 Cardiovascular Research Center (CSIC-ICCC), IIB-Sant Pau, Barcelona, Spain
Lipids in Health and Disease 2011, 10:175 doi:10.1186/1476-511X-10-175Published: 10 October 2011
Epidemiologic studies indicate a strong inverse correlation between plasma levels of high-density lipoproteins (HDL) and cardiovascular disease (CVD). The most relevant cardioprotective mechanism mediated by HDL is thought to be reverse cholesterol transport (RCT). New insights in HDL biology and RCT have allowed the development of promising agents aimed to increase HDL function and promote atherosclerosis regression. In this regard, apo-AI analogs and CETP inhibitors dalcetrapib and anacetrapib have aroused a great interest and opened new expectations in the treatment of CVD.